Back to search

Peptide record

TPDB92088

BLP-7 Antibacterial Anticancer Antifungal Antiparasitic Toxicity standard
27 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92088
BLP-7
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia CancerPPD 2.0 dbACP Antifungipept CAFPdb ToxinPred 3.0
standard
No
A 27-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
GIGGALLSAGKSALKGLAKGLAEHFAN-NH2
Physicochemical Analysis
C114H191N33O33
RDCQMPTWYV
AG
2551.97
10.32
4
1
13
+2
1.43
0.415
108.89
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
3
Residue Composition
number
6
A
0
R
1
N
0
D
0
C
1
E
0
Q
6
G
1
H
1
I
5
L
3
K
0
M
1
F
0
P
2
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 6 R: 0 N: 1 D: 0 C: 0 E: 1 Q: 0 G: 6 H: 1 I: 1 L: 5 K: 3 M: 0 F: 1 P: 0 S: 2 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
27
C114H191N33O33
2551.97
10.32
+2
1.43
0.415
Amidation
L
Linear
Free
Antimicrobial
Bombina orientali
Evidence Records 6 records
Evidence 1 Activity

Activity

IC50
IC50 = 0.61 µM
Anticancer
0.61 µM

Target

Liver Cancer
SK-HEP-1
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 2.83 µM
Anticancer
2.83 µM

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 3 Activity

Activity

IC50
IC50 = 1.81 µM
Anticancer
1.81 µM

Target

Liver Cancer
Huh-7
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 4 Activity

Activity

Cell Viability
Cell Viability ~ 20% at 2.5 µM
Anticancer
~20 % at 2.5 µM

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 5 Activity

Activity

Cell Viability
Cell Viability ~ 20% at 2.5 µM
Anticancer
~20 % at 2.5 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 6 Activity

Activity

Cell Viability
Cell Viability < 20% at 10 µM
Anticancer
<20 % at 10 µM

Target

Skin Cancer
A-375
Skin

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018